Findings

What do systematic reviews say?

4,929 questions · 15,174 findings · 2,372 reviews

Sort:Best matchNewestHighest certainty Download CSV

No studies found 15,174 · 100%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Summary of findings table ‐ Oral classical immunosuppressants (prednisolone or cyclosporine) vs placebo

Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata

The review found no eligible studies for this question.

1 finding from 1 review

Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Contact immunotherapy (diphencyprone) + hair growth stimulants (minoxidil) vs contact immunotherapy (diphencyprone)

Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata

The review found no eligible studies for this question.

1 finding from 1 review

Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Minoxidil vs placebo

Health‐related quality of life ‐ not reported · adults with alopecia areata

The review found no eligible studies for this question.

1 finding from 1 review

Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Minoxidil vs placebo

Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata

The review found no eligible studies for this question.

1 finding from 1 review

Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Other therapies (cryotherapy) vs other therapies (fractional CO2 laser)

Health‐related quality of life ‐ not reported · adults with alopecia areata

The review found no eligible studies for this question.

1 finding from 1 review

Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Other therapies (cryotherapy) vs other therapies (fractional CO2 laser)

Long‐term hair regrowth ≥ 75% ‐ not reported · adults with alopecia areata

The review found no eligible studies for this question.

1 finding from 1 review

Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Oral classical immunosuppressants (betamethasone) vs oral classical immunosuppressants (azathioprine, methotrexate, prednisolone)

Health‐related quality of life ‐ not reported · adults with alopecia areata

The review found no eligible studies for this question.

1 finding from 1 review

Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Oral classical immunosuppressants (betamethasone) vs oral classical immunosuppressants (azathioprine, methotrexate, prednisolone)

Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata

The review found no eligible studies for this question.

1 finding from 1 review

Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Digital technology (TIM) vs standard treatment (TBM)

Treatment burden · children aged 5 to 16 years

The review found no eligible studies for this question.

1 finding from 1 review

Digital technology for monitoring adherence to inhaled therapies in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Digital technology (TIM) vs standard treatment (TBM)

QoL · children aged 5 to 16 years

The review found no eligible studies for this question.

1 finding from 1 review

Digital technology for monitoring adherence to inhaled therapies in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Digital technology (TIM) vs standard treatment (TBM)

Pulmonary exacerbations · children aged 5 to 16 years

The review found no eligible studies for this question.

1 finding from 1 review

Digital technology for monitoring adherence to inhaled therapies in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Standard‐protein formula vs low‐protein formula

Overweight · healthy, full‐term (37 to 42 weeks), formula‐fed infants

The review found no eligible studies for this question.

1 finding from 1 review

Higher versus lower protein intake in formula‐fed term infants 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Standard‐protein formula vs low‐protein formula

Obesity · healthy, full‐term (37 to 42 weeks), formula‐fed infants

The review found no eligible studies for this question.

1 finding from 1 review

Higher versus lower protein intake in formula‐fed term infants 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Standard‐protein formula vs low‐protein formula

All‐cause mortality · healthy, full‐term (37 to 42 weeks), formula‐fed infants

The review found no eligible studies for this question.

1 finding from 1 review

Higher versus lower protein intake in formula‐fed term infants 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

High‐protein formula vs standard‐protein formula

All‐cause mortality · healthy, full‐term (37 to 42 weeks), formula‐fed infants

The review found no eligible studies for this question.

1 finding from 1 review

Higher versus lower protein intake in formula‐fed term infants 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Class I and/or III antiarrhythmics vs control

Outcomes at > 3 to 6 months after ablation · Human trial participants undergoing ablation for atrial fibrillation

The review found no eligible studies for this question.

1 finding from 1 review

Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Class I antiarrhythmics vs control

Adverse events: thromboembolic events · Human trial participants undergoing ablation for atrial fibrillation

The review found no eligible studies for this question.

1 finding from 1 review

Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Class I antiarrhythmics vs control

Adverse events: myocardial infarction · Human trial participants undergoing ablation for atrial fibrillation

The review found no eligible studies for this question.

1 finding from 1 review

Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Class I antiarrhythmics vs control

Adverse events: new diagnosis of heart failure · Human trial participants undergoing ablation for atrial fibrillation

The review found no eligible studies for this question.

1 finding from 1 review

Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Class I antiarrhythmics vs control

All‐cause mortality · Human trial participants undergoing ablation for atrial fibrillation

The review found no eligible studies for this question.

1 finding from 1 review

Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found